RESEARCH TRIANGLE PARK, NC--(Marketwire - October 22, 2009) - Drug companies are carefully navigating the current stretch of industry consolidation as giants merge and promising small firms seek interested buyers.

With conditional FDA clearance earlier this month, Pfizer and Wyeth merged in one of the largest corporate marriages of all time. The new organization will manage a merged portfolio of products that the FDA described as 'highly complementary.' Despite that promise, however, concerns remain about the merger's effect on issues ranging from long-term shareholder value to the retention of talented employees.

"In some ways, mega-deals like this one create more questions than answers," says Jason Richardson, president of Cutting Edge Information. "It will be years before we know how effective this merger actually was."

While the media focuses on large deals such as this one or the yet-to-close Merck/Schering-Plough merger, most acquisitions lack the flash to make major headlines. The bulk of M&A activity involves smaller organizations. The past year has been especially active for such mergers, according to "Pharmaceutical Mergers and Acquisitions," ( a new report from Cutting Edge Information.

"Pressure from both sides of a deal drives the merger activity we're seeing," says Richardson. "Larger companies make acquisitions to position themselves in certain markets and to prepare for patent expirations. A lot of smaller and startup companies, meanwhile, face tremendous financial pressure as operating capital dwindles and access to funding remains tight."

The Cutting Edge Information report covers the drivers and financing of M&A activity over the past year, and it describes how companies deal with the most challenging integration problems. With this report, readers grasp key components of M&A success:

--  Get a feel for the current M&A landscape: learn what drives
    acquisition strategies for top companies -- and how other organizations
    seek suitors for their own sales.
--  Build an M&A plan that focuses on key goals, avoids costly mistakes,
    and realizes deal potential as quickly as possible.
--  Complete integration as quickly as possible to boost productivity and
    realize deal potential.
--  Build an integration timeline to avoid common operational and cultural
--  Clarify roles, responsibilities and career paths to avoid costly
    attrition and retain valuable employees.
--  Gather perspectives and predictions on future deals from the very
    managers that execute them.

For a complimentary brochure of this report, visit

Contact Information: CONTACT: Stephanie Swanson 919-433-0212